Генетически детерминированный тип ацетилирования изониазида и клиническое течение коинфекции ВИЧ/туберкулёз
https://doi.org/10.37489/2588-0527-2021-2-12-13
Abstract
Цель. Сравнить частоты сочетаний генотипов rs1799929 (481C>Т), rs1799930 (590G>A) и rs1208 (803A>G) у госпитализированных пациентов с ВИЧ/ТБ, получавших АРТ и ПТТ, с различными исходами лечения.
About the Authors
Н. МальцеваRussian Federation
О. Казанцева
Russian Federation
References
1. Bhatt NB, Barau C, Amin A, Baudin E, Meggi B, Silva C, Furlan V, Grinsztejn B, Barrail-Tran A, Bonnet M, Taburet AM. Pharmacokinetics of Rifampin and Isoniazid in Tuberculosis-HIV-Coinfected Patients Receiving Nevirapine- or Efavirenz-Based Antiretroviral Treatment. Antimicrob Agents Chemother. 2014 ;58(6):3182–3190. DOI: 10.1128/AAC.02379-13.
2. Chirehwa MT, McIlleron H, Wiesner L, Affolabi Di, Bah-Sow O, Merle C, Denti P. Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid. J Antimicrob Chemother. 2019;74(1):139–148. DOI: 10.1093/jac/dky378.
3. Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES. Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey. PloS ONE. 2011;6(4):e18507. DOI: 10.1371/journal.pone.0018507.
4. Boukouvala S. Human NAT2 Alleles (Haplotype). 2019. http://nat.mbg.duth.gr/Human%20NAT2%20alleles_2013.htm
Review
For citations:
, . Pharmacogenetics and Pharmacogenomics. 2021;(2):12-13. (In Russ.) https://doi.org/10.37489/2588-0527-2021-2-12-13